| __timestamp | Sarepta Therapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 40786000 |
| Thursday, January 1, 2015 | 75043000 | 47876000 |
| Friday, January 1, 2016 | 83749000 | 52035000 |
| Sunday, January 1, 2017 | 122682000 | 55348000 |
| Monday, January 1, 2018 | 207761000 | 65276000 |
| Tuesday, January 1, 2019 | 284812000 | 82720000 |
| Wednesday, January 1, 2020 | 317875000 | 89118000 |
| Friday, January 1, 2021 | 282660000 | 181193000 |
| Saturday, January 1, 2022 | 451421000 | 174078000 |
| Sunday, January 1, 2023 | 481871000 | 184232000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Sarepta Therapeutics, Inc. and Veracyte, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Veracyte's expenses increased by approximately 350%, indicating a more measured approach. Notably, in 2023, Sarepta's SG&A expenses were more than double those of Veracyte, highlighting its significant investment in administrative and sales functions. This divergence in financial strategy underscores the varied paths companies can take in the competitive biotech landscape. As these companies continue to evolve, monitoring such financial metrics will be key to understanding their future directions.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Veracyte, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Veracyte, Inc. or Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Comparing SG&A Expenses: Veracyte, Inc. vs Xencor, Inc. Trends and Insights